Trial Profile
A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of ARRY-502 in Adults With Persistent Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs ARRY 502 (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- Sponsors Array BioPharma; Pfizer
- 04 Mar 2014 Results presented at the 70th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 23 Jul 2013 Top-line results reported in an Arrray BioPharma media release.
- 23 Jul 2013 Primary endpoint 'Forced-expiratory-volume-in-1-second' has been met, according to an Arrray BioPharma media release.